Alice T Shaw

Summary

Affiliation: Massachusetts General Hospital
Country: USA

Publications

  1. ncbi ALK in lung cancer: past, present, and future
    Alice T Shaw
    Massachusetts General Hospital Cancer Center, Boston, MA 02114, USA
    J Clin Oncol 31:1105-11. 2013
  2. ncbi Pemetrexed-based chemotherapy in patients with advanced, ALK-positive non-small cell lung cancer
    A T Shaw
    Department of Medicine Hematology Oncology, Massachusetts General Hospital Cancer Center, Boston, MA 02114, USA
    Ann Oncol 24:59-66. 2013
  3. ncbi Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis
    Alice T Shaw
    Massachusetts General Hospital Cancer Center, Boston, MA, USA
    Lancet Oncol 12:1004-12. 2011
  4. ncbi Targeting anaplastic lymphoma kinase in lung cancer
    Alice T Shaw
    Thoracic Oncology Center, Massachusetts General Hospital Cancer Center, Boston, Massachusetts 02114, USA
    Clin Cancer Res 17:2081-6. 2011
  5. ncbi Future of early detection of lung cancer: the role of mouse models
    Alice T Shaw
    Center for Cancer Research and Department of Biology, Massachusetts Institute of Technology, Cambridge, MA, USA
    Clin Cancer Res 11:4999s-5003s. 2005
  6. ncbi Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers
    Ryohei Katayama
    Massachusetts General Hospital Cancer Center, Boston, MA 02129, USA
    Sci Transl Med 4:120ra17. 2012
  7. ncbi Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer
    Eunice L Kwak
    Massachusetts General Hospital Cancer Center, Boston, MA 02114, USA
    N Engl J Med 363:1693-703. 2010
  8. ncbi ROS1 rearrangements define a unique molecular class of lung cancers
    Kristin Bergethon
    Massachusetts General Hospital, Boston, MA 02114 2696, USA
    J Clin Oncol 30:863-70. 2012
  9. ncbi A phase I study of erlotinib and hydroxychloroquine in advanced non-small-cell lung cancer
    Sarah B Goldberg
    Massachusetts General Hospital Cancer Center, Boston, MA, USA
    J Thorac Oncol 7:1602-8. 2012
  10. ncbi Crizotinib and testing for ALK
    Alice T Shaw
    Massachusetts General Hospital Cancer Center, Boston, MA, USA
    J Natl Compr Canc Netw 9:1335-41. 2011

Research Grants

  1. Ras Signaling in Development and Cancer
    Alice Shaw; Fiscal Year: 2007

Collaborators

Detail Information

Publications18

  1. ncbi ALK in lung cancer: past, present, and future
    Alice T Shaw
    Massachusetts General Hospital Cancer Center, Boston, MA 02114, USA
    J Clin Oncol 31:1105-11. 2013
    ..In this review, we will discuss the history of this field, current diagnostic and treatment practices, and future challenges and opportunities to advance outcomes for patients with ALK-positive lung cancers...
  2. ncbi Pemetrexed-based chemotherapy in patients with advanced, ALK-positive non-small cell lung cancer
    A T Shaw
    Department of Medicine Hematology Oncology, Massachusetts General Hospital Cancer Center, Boston, MA 02114, USA
    Ann Oncol 24:59-66. 2013
    ....
  3. ncbi Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis
    Alice T Shaw
    Massachusetts General Hospital Cancer Center, Boston, MA, USA
    Lancet Oncol 12:1004-12. 2011
    ....
  4. ncbi Targeting anaplastic lymphoma kinase in lung cancer
    Alice T Shaw
    Thoracic Oncology Center, Massachusetts General Hospital Cancer Center, Boston, Massachusetts 02114, USA
    Clin Cancer Res 17:2081-6. 2011
    ..Current efforts seek to expand the role of ALK kinase inhibition in lung and other cancers and to address the molecular basis for the development of resistance...
  5. ncbi Future of early detection of lung cancer: the role of mouse models
    Alice T Shaw
    Center for Cancer Research and Department of Biology, Massachusetts Institute of Technology, Cambridge, MA, USA
    Clin Cancer Res 11:4999s-5003s. 2005
    ..The application of innovative technologies to accurate mouse models promises to accelerate the discovery of new molecular targets and imaging biomarkers for the early detection of lung cancer...
  6. ncbi Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers
    Ryohei Katayama
    Massachusetts General Hospital Cancer Center, Boston, MA 02129, USA
    Sci Transl Med 4:120ra17. 2012
    ....
  7. ncbi Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer
    Eunice L Kwak
    Massachusetts General Hospital Cancer Center, Boston, MA 02114, USA
    N Engl J Med 363:1693-703. 2010
    ..We explored the therapeutic efficacy of inhibiting ALK in such tumors in an early-phase clinical trial of crizotinib (PF-02341066), an orally available small-molecule inhibitor of the ALK tyrosine kinase...
  8. ncbi ROS1 rearrangements define a unique molecular class of lung cancers
    Kristin Bergethon
    Massachusetts General Hospital, Boston, MA 02114 2696, USA
    J Clin Oncol 30:863-70. 2012
    ..Because little is known about these tumors, we examined the clinical characteristics and treatment outcomes of patients with NSCLC with ROS1 rearrangement...
  9. ncbi A phase I study of erlotinib and hydroxychloroquine in advanced non-small-cell lung cancer
    Sarah B Goldberg
    Massachusetts General Hospital Cancer Center, Boston, MA, USA
    J Thorac Oncol 7:1602-8. 2012
    ..This investigator-initiated study explores the safety, maximum tolerated dose, clinical response, and pharmacokinetics of hydroxychloroquine (HCQ) with and without erlotinib in patients with advanced non-small-cell lung cancer...
  10. ncbi Crizotinib and testing for ALK
    Alice T Shaw
    Massachusetts General Hospital Cancer Center, Boston, MA, USA
    J Natl Compr Canc Netw 9:1335-41. 2011
    ....
  11. ncbi Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study
    Pasi A Janne
    Lowe Center for Thoracic Oncology and the Belfer Institute for Applied Cancer Science, Dana Farber Cancer Institute, Boston, MA 02215, USA
    Lancet Oncol 14:38-47. 2013
    ..We did a prospective, randomised, phase 2 trial to assess selumetinib plus docetaxel in previously treated patients with advanced KRAS-mutant NSCLC...
  12. ncbi Variants on a theme: a biomarker of crizotinib response in ALK-positive non-small cell lung cancer?
    Adam S Crystal
    Massachusetts General Hospital Cancer Center and Department of Medicine, Harvard Medical School, Boston, MA 02114, USA
    Clin Cancer Res 18:4479-81. 2012
    ..The particular ALK fusion expressed may have an impact on protein stability and sensitivity to crizotinib, and this may underlie the heterogeneity in responses observed in the clinic...
  13. ncbi Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors
    Lecia V Sequist
    Massachusetts General Hospital Cancer Center, Boston, MA 02114, USA
    Sci Transl Med 3:75ra26. 2011
    ..Collectively, these results deepen our understanding of resistance to EGFR inhibitors and underscore the importance of repeatedly assessing cancers throughout the course of the disease...
  14. ncbi Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK
    Alice T Shaw
    Department of Pathology, Massachusetts General Hospital, Warren 501c, 55 Fruit St, Boston, MA 02114, USA
    J Clin Oncol 27:4247-53. 2009
    ..To aid in identification and treatment of these patients, we examined the clinical characteristics and treatment outcomes of patients who had NSCLC with and without EML4-ALK...
  15. ncbi Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK
    Ryohei Katayama
    Massachusetts General Hospital Cancer Center, Boston, MA 02129, USA
    Proc Natl Acad Sci U S A 108:7535-40. 2011
    ..Thus, we have developed a model of acquired resistance to ALK inhibitors and have shown that second-generation ALK TKIs or Hsp90 inhibitors are effective in treating crizotinib-resistant tumors harboring secondary gatekeeper mutations...
  16. ncbi New targets in advanced NSCLC: EML4-ALK
    Adam S Crystal
    Massachusetts General Hospital Cancer Center Center, Boston, MA 02114, USA
    Clin Adv Hematol Oncol 9:207-14. 2011
    ..Here we review the discovery of EML4-ALK, the development of clinical diagnostics for ALK rearrangements, the clinical epidemiology of lung cancers driven by EML4-ALK, and ongoing ALK inhibitor-based clinical trials...
  17. ncbi Selective killing of K-ras mutant cancer cells by small molecule inducers of oxidative stress
    Alice T Shaw
    Koch Institute for Integrative Cancer Research, Department of Biology, Massachusetts Institute of Technology, Cambridge, MA 02139, USA
    Proc Natl Acad Sci U S A 108:8773-8. 2011
    ..Our findings establish the specific antitumor activity of lanperisone and reveal oxidative stress pathways as potential targets in Ras-mediated malignancies...
  18. ncbi Sprouty-2 regulates oncogenic K-ras in lung development and tumorigenesis
    Alice T Shaw
    Center for Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, and Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston 02114, USA
    Genes Dev 21:694-707. 2007
    ..These findings indicate that in the lung, Sprouty-2 plays a critical role in the regulation of oncogenic K-ras, and implicate counter-regulatory mechanisms in the pathogenesis of Ras-based disease...

Research Grants2

  1. Ras Signaling in Development and Cancer
    Alice Shaw; Fiscal Year: 2007
    ..Aim 3 will test whether induction of Ras/MAPK antagonists plays a role in Ras transformation in vitro and Ras-induced lung tumorigenesis in vivo. ..